Real-world Secukinumab Outcomes in Canadian HS Patients

Sponsor
Novartis Pharmaceuticals
Study ID
NCT07282015
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 100 Years
Healthy Volunteers
Not accepted

Study Details

The HS-RISE study aims to assess real-world HS treatment outcomes and patterns, safety of secukinumab, and to describe the baseline characteristics of patients diagnosed with moderate-to- severe HS who are prescribed secukinumab in Canadian routine clinical practice.

Key Dates

First listed
Dec 15, 2025
Start date
Dec 12, 2025
Status verified
Jun 2026
Primary completion
Feb 11, 2028
Completion
Feb 11, 2028

Study Design

Enrollment
142 participants (estimated)

Arms

  • Arm: Secukinumab
    Patients with moderate-to-severe HS who are prescribed secukinumab in Canadian routine clinical practice

Primary Outcome Measure

Proportion of patients who experience a change in disease severity classification [ Time Frame: Baseline, month 12 ]

Central Contacts

Find similar trials

Nationwide
Hidradenitis suppurativa trialsDermatology trialsRheumatology trialsAutoimmune disease trials

Related Studies